We also showed that metformin restores crizotinib sensitivity in crizotinib-resistant NSCLC cells through the inhibition of the insulin-like growth factor 1 receptor (IGF1-R) signalling pathway16. Here, IGF1R is linked to non-small cell lung carcinoma.